#Fludarabine

[return-of-the-prodigal-daughter]

HOUSE: CIA headquarters. How much fludarabine...?

WILSON: Either you're sprawled naked on your floor with an empty bottle of Vicodin, or collapsed naked in front of your computer with an empty bottle of Viagra. Please tell me which, because Chase has another pool going.

HOUSE: They flew me in to help deal with a sick employee. How much...?

WILSON: Hallucinations. Damn! I shouldn't have bet on the Viagra.

This while interaction is actually so funny

[dramamath]

Some good news to share: as of today, I have reached three years of progression free survival (PFS), to be verified by my next set of labs on Friday. With chronic leukemia, remission isn’t a realistic goal. Leukemic cells can hide throughout the blood stream, lymphatic system, and bone marrow. A long PFS is the hope, and in my situation, that hope is strong. If I continue to be in PFS for 10.4 years, I will likely never relapse. I’ll explain.

Chemotherapy in the treatment of CLL is rare these days. CLL patients are not the same. There are different genetic markers (such as deleted genes on chromosome 13 or chromosome 17, or as in my case, trisomy 12 (an extra copy of chromosome 12 in my lymphocyte cells)).

Another important marker is the immunoglobulin heavy-chain variable region (IgHV). About 15% of CLL patients are IgHV mutated. This is one case in which a genetic mutation is good, for these patients have a better prognosis. I am in that 15%. IgHV mutated patients who are young (at 51 three years ago, I was considered young) are the only patients who are considered for chemoimmunotherapy. For CLL, this is a three drug regimen of fludarabine, cyclophosphamide, and rituximab (FCR).

The success of most cancer treatments are measured in median PFS or median overall survival (OS), the point where more than 50% of patients relapse or die as a result of the leukemia. For IgHV mutated CLL patients who go through the FCR regimen, that level has never been reached. In fact, there is not a single documented case of relapse beyond 10.4 years after treatment began.

So I continue my slow march to April 1, 2030. Ironically, this will be exactly ten years from the date of my final treatment.

[zany1122]

Fludacel 50mg Injection

Fludacel 50 injection is used in the treatment of B-Cell chronic lymphocytic leukemia (blood cancer). Know about the working, benefits, drug interactions, and safety precautions. Buy fludarabine injection online on GNH India at best PRICE.

READ MORE:https://www.gnhindia.com/products/flu-lifex-50mg-fludarabine-phosphate/

[adoctorx]

Arzerra (ofatumumab) is a prescription drug that’s used to treat chronic lymphocytic leukemia. The drug comes as a liquid solution for infusion by a healthcare professional. You’ll receive Arzerra on a schedule determined by your doctor. Arzerra is used in adults to treat chronic lymphocytic leukemia (CLL). It’s used for: CLL that hasn’t been treated previously in people who can’t be treated with a drug called fludarabine (Fludara). For this use, Arzerra is used in combination with a chemotherapy drug called chlorambucil (Leukeran). CLL that has relapsed (come back). For this use, Arzerra is used with the chemotherapy drugs fludarabine and cyclophosphamide. Long-term treatment of progressive or recurrent* CLL in people who’ve previously had a partial or complete response** to at least two types of therapy. It’s also used for CLL that has not improved after treatment with fludarabine and alemtuzumab (Lemtrada). The active ingredient in Arzerra is ofatumumab. (An active ingredient is what makes a drug work.) Arzerra belongs to a group of drugs called monoclonal antibodies. It’s a biologic drug, which means it’s made from living cells. This article describes the dosages of Arzerra, as well as its strengths and how it’s given. To learn more about Arzerra, see this in-depth article. * Progressive means the cancer is getting worse. Recurrent means the cancer has returned. ** A complete response to treatment is when tests show no more cancer in your blood. A partial response is when the level of cancer has decreased by 50% or more. Boxed warnings Arzerra has boxed warnings about the risk of reactivation of hepatitis B virus, and the risk of progressive multifocal leukoencephalopathy (PML). A boxed warning is the most serious warning from the Food and Drug Administration (FDA). It alerts doctors and patients about drug effects that may be dangerous. Risk of hepatitis B reactivation. If you’ve had hepatitis B infection in the past, treatment with Arzerra may reactivate the virus in your body. This means the virus becomes active again, which may cause symptoms of hepatitis B. These symptoms can include weakness, nausea and vomiting, loss of appetite, and jaundice. In rare cases, reactivation of hepatitis B can cause liver failure or even death. Before you begin treatment with Arzerra, your doctor will do blood tests to check if you have hepatitis B. If you do, they’ll treat the infection and discuss whether it’s safe for you to use Arzerra. During treatment with Arzerra, your doctor will monitor you for signs of hepatitis B reactivation. They’ll also monitor you for at least 12 months after your Arzerra treatment ends. Risk of progressive multifocal leukoencephalopathy. Treatment with Arzerra may increase your risk for progressive multifocal leukoencephalopathy (PML). PML is a serious viral infection that affects your brain. In rare cases, it may cause death. While you’re on Arzerra therapy, your doctor will monitor you for signs of PML. These can include changes in personality, weakness, vision problems, or trouble speaking. If you develop PML, your doctor will stop your Arzerra treatment and treat the PML. They’ll also determine whether you’ll continue receiving Arzerra. If you have questions about these serious side effects of Arzerra, talk with your doctor. What is Arzerra’s dosage? This section describes the usual dosages of Arzerra. Keep reading to learn more. What is Arzerra’s form? Arzerra is available as a liquid solution that’s given as an intravenous (IV) infusion by a healthcare professional in a clinic or hospital. An infusion is a slow injection into your vein over a period of time. What strength does Arzerra come in? Arzerra comes in two strengths: 100 milligrams (mg) per 5 milliliters (mL) 1,000 mg per 50 mL What are the usual dosages of Arzerra? Your doctor will likely start you on a low dosage of Arzerra and adjust the dosage over time until you reach the amount that’s right for you.

They’ll ultimately prescribe the lowest dosage that provides the desired effect. The information below describes dosages that are commonly used or recommended. Your doctor will determine the best dosage to fit your needs. Dosage for chronic lymphocytic leukemia (CLL) The typical Arzerra dosage for adults with CLL depends on several factors. These include the type of CLL being treated, whether you’ve had treatment before, and whether you can take certain types of drugs. The table below describes the dosage for all four types of Arzerra treatment. Arzerra dosage for first-time treatment of CLL If you’ve never been treated for CLL before, Arzerra is given in combination with chlorambucil (Leukeran) in 28-day dosage cycles. (Your doctor will tell you the dosage needed for chlorambucil.) CyclesArzerra infusion doseCycle 1, day 1300 mg given over 4–5 hoursCycle 1, day 8 (1 week later)1,000 mg given over about 4 hoursCycle 2, day 1, and continued treatment in 28-day cycles with a minimum of 3 cycles and a maximum of 12 cycles1,000 mg given over about 4 hours Cycle 1: You’ll receive two doses of Arzerra. On day 1 of treatment, you’ll receive 300 mg of Arzerra by infusion over 4–5 hours. Then on day 8, you’ll receive 1,000 mg on day 1 of subsequent 28-day cycles. Cycle 2 and following cycles: You’ll receive 1,000 mg of Arzerra over about 4 hours on day 1 of a 28-day treatment cycle. You’ll receive this dosage for at least three 28-day cycles and up to 12 cycles, depending on how your body responds to treatment. Dosage for relapsed CLL To treat CLL that has relapsed (come back), Arzerra is given in combination with the drugs fludarabine and cyclophosphamide. (Your doctor will tell you the dosage needed for fludarabine and cyclophosphamide.) ScheduleArzerra infusion doseCycle 1, day 1300 mg given over 4–5 hoursCycle 1, day 8 (1 week later)1,000 mg given over about 4 hoursCycle 2, day 1, and continued treatment in 28-day cycles with a maximum of 6 cycles1,000 mg given over about 4 hours Cycle 1: You’ll receive two doses of Arzerra. On day 1 of treatment, you’ll receive 300 mg of Arzerra by infusion over 4 to 5 hours. On day 8, you’ll receive 1,000 mg on day 1 of subsequent 28-day cycles. Cycle 2 and following cycles: You’ll receive 1,000 mg of Arzerra by infusion over about 4 hours on day 1 of a 28-day treatment cycle. You’ll receive this dosage for up to 6 cycles, depending on how your body responds to treatment. Dosage for long-term treatment of CLL that has responded to previous treatment Arzerra is also used for long-term treatment of recurrent or progressive CLL that has been treated with at least two other types of therapy. For this use, you’ll receive Arzerra without other medications. ScheduleArzerra infusion doseDay 1300 mg given over 4–5 hoursDay 8 (1 week later)1,000 mg given over about 4 hours7 weeks later, and then every 8 weeks for a maximum of 2 years1,000 mg given over about 4 hours On day 1 of treatment, you’ll receive 300 mg of Arzerra by infusion over 4–5 hours. Then on day 8 (1 week later), you’ll receive Arzerra 1,000 mg over about 4 hours. Seven weeks later, you’ll receive 1,000 mg of Arzerra by infusion over about 4 hours. After that, every 8 weeks you’ll receive a 1,000-mg dose of Arzerra over about 4 hours, for a maximum of 2 years. Dosage for CLL that’s stopped responding to certain treatments To treat CLL that’s stopped responding to the drugs fludarabine and alemtuzumab, you’ll receive 12 total doses of Arzerra on a dosing schedule. ScheduleArzerra infusion doseDay 1300 mg given over about 7 hoursDay 8 (1 week later), and then doses once per week for 6 more doses2,000 mg given over about 7 hours4 weeks later, and then doses once every 4 weeks for 3 more doses2,000 mg given over about 4 hours On day 1 of treatment, you’ll receive 300 mg of Arzerra by infusion over about 7 hours. Then starting on day 8, you’ll receive 2,000 mg of Arzerra once per week for 7 doses. After this, you’ll receive Arzerra once every 4 weeks for 4 doses.

Is Arzerra used long term? How long you’ll receive treatment with Arzerra depends on factors such as the type of CLL being treated. You’ll receive Arzerra treatment on a dosing schedule that your doctor will determine. You’ll receive Arzerra: for up to 12 months for first-time treatment of CLL for up to 6 months for CLL that’s relapsed (returned) for up to 2 years as an extended treatment for recurrent or progressive CLL for up to 6 months for CLL that hasn’t responded to other types of treatment If you have questions about how long you’ll receive treatment with Arzerra, talk with your doctor. Dosage adjustments Your doctor may adjust your dosage of Arzerra if you have certain infusion-related side effects of the medication. If you have questions about dosage adjustments for Arzerra, talk with your doctor. What factors can affect my dosage? The dosage of Arzerra you’re prescribed may depend on several factors. These include: the type and severity of CLL you’re using the drug to treat your response to treatment side effects you may experience other medications you may be taking How is Arzerra given? Arzerra is available as a liquid solution that’s given as an intravenous (IV) infusion. An infusion is an injection into your vein over a period of time. You’ll receive infusions at a hospital or a clinic. Your doctor will monitor you closely while you receive doses of Arzerra. For your first dose of Arzerra for first-time treatment of CLL, CLL that’s relapsed (returned), or extended treatment for recurrent or progressive CLL, the infusion may take up to 4–5 hours. After this, it may take less time to receive doses of Arzerra. For your first and second doses of Arzerra for CLL that hasn’t responded to other types of treatment, the infusion may take up to 7 hours. After this, it may take less time to receive doses of Arzerra. Your doctor may give doses of Arzerra with certain medications to prevent infusion-related reactions. Examples of these medications include: a fever reducer, such as Tylenol (acetaminophen) corticosteroids such as dexamethasone antihistamines such as Benadryl (diphenhydramine) Examples of infusion-related reactions include: fever shortness of breath itching or rash at the infusion site low blood pressure or high blood pressure chest pain Your doctor may slow, pause, or stop Arzerra treatment if you have infusion reactions. If you have serious or life-threatening infusion reactions, your doctor will stop treatment with Arzerra and discuss safer treatment options with you. What if I miss a dose? If you miss an appointment to receive a dose of Arzerra, call your doctor’s office as soon as possible to reschedule. They’ll schedule a time for you to receive the missed dose and adjust your dosing schedule if needed. If you need help remembering your appointments, try downloading a reminder app on your phone. Frequently asked questions Below are answers to some commonly asked questions about Arzerra’s dosage. Is Arzerra’s dosage similar to the dosage of Copiktra? No. Arzerra (ofatumumab) and Copiktra (duvelisib) are both used to treat CLL that’s relapsed or hasn’t responded to certain other treatments. However, their forms and dosages are different. Arzerra comes as a liquid solution that’s given via intravenous (IV) infusion by a healthcare professional in a hospital or clinic. Copiktra, on the other hand, comes as oral capsules. How often Arzerra is given depends on factors such as the reason for treatment of CLL. After the first two doses, Arzerra is typically given once per month or less frequently over several months. Copiktra is taken twice per day. To learn more about how these drugs compare, talk with your doctor. How long does it take for Arzerra to start working? Arzerra starts to work after your first dose. Because of how the drug works, you likely won’t feel the drug working in your body.

But your doctor will do regular tests during treatment to check whether Arzerra is working to treat your condition. If you have other questions about what to expect from your Arzerra treatment, talk with your doctor. What should I ask my doctor? The sections above describe the usual dosages provided by Arzerra’s manufacturer. If your doctor recommends this drug, they’ll prescribe the dosage that’s right for you. Talk with your doctor if you have questions or concerns about your current dosage. Here are some examples of questions you may want to ask your doctor: Will you lower my dosage if I have side effects from Arzerra? Would I need to continue my Arzerra dosage for longer than 2 years for extended treatment of CLL? How does the dosage of Arzerra compare with the dosage of Gazyva (obinutuzumab)? To learn more about Arzerra, see these articles: Arzerra (ofatumumab) Side Effects of Arzerra: What You Need to Know

[hlgfy-blog]

New Birthday: December 21

Jake is a 26 year old german man as of 5pm on 12/21. Danke Shoen whoever you are.

He was admitted on 12/13, chemo 12/14-12/17, radiation 12/18, NK Cell Therapy 12/19, Day of Rest 12/20, Transplant 12/21.

The chemo was interesting - Fludarabine + Methaline. The latter causes mouth sores (around 10 days after) and in an attempt to combat that you chew ice for essentially 2 hours over the course of the administration. The cold shrinks the capillaries in your mouth and restricts the amount of chemo that ends up there.

Similarly to last time, he got Benadryl + Tylenol to get head of any preservative reactions. Last time he got steroids but they can effect the efficacy of the NK cells so just Benadryl this time. The smell of the preservative is very strong and lasts for a few days. When walking the halls you can easily identify which patient/room has just had a transplant.

Last time he got two bags of stem cells. This time he got three bags of stems cells. They are hung consecutively and Nurse Mike did an excellent job making sure every last cell was squeezed out of each bag. The whole process took about 1.5 hours.

Onto the waiting and watching phase. He does get two more days of (a different) chemo on Day +3 and Day +4 and two more NK cell infusions. One inpatient on Day + 7 and one of Day +28. He will likely have ups and downs over the next few weeks but it should be pre-transplant and post-transplant side effects.

[nursingscience]

DRUG OF CHOICE SERIES

ANTICANCER DRUGS

▪️Drug of choice for breast cancer - Tamoxifen

▪️Drug of choice for glioma - Nitrosourea

▪️Drug of choice for colorectal cancer - 5 Fluorouracil

▪️Drug of choice for choriocarcinoma - Methotrexate

▪️Drug of choice for pancreatic carcinoma - Gemcitabine

▪️First line chemotherapy for cervix carcinoma - Cisplatin

▪️Drug of choice for the brain tumor - Lomustine

▪️Drug of choice for prostate carcinoma - Flutamide

▪️Drug of choice for insulinoma - Streptozotocin

▪️Drug of choice for polycythemia vera - Busulphan or Chlorambucil

▪️Drug of choice for carcinoma of endometrium - Progestins

▪️Drug of choice for kaposi sarcome - IF2 alpha

▪️Drug of choice for CLL - Chlorambucil or Fludarabine

▪️Drug of choice for acute myelocytic leukemia - Cytarabine with Mitoxantrone

▪️Drug of choice for wilm's tumor - Vincristine with Danctinomycin

▪️Drug of choice for acute promyeloblastic leukemia - Retinoic acid

▪️Drug of choice for hairy cell leukemia - Cladarabine

▪️Drug of choice for thyroid carcinoma-1-131 with Doxarubicin and cisplatin

▪️Drug of choice for stomach cancer - Fluorouracil with Cisplatin

▪️Drug of choice for CML-Imatinib or Busulfan

▪️Drug of choice for acute lymphocytic leukemia (ALL) - Vincristine +Prednisolone +Mercaptopurine + Cyclophosphamide +Methotrexate

▪️Drug of choice for ovarian cancer - Cisplatin with Paclitaxel

▪️Drug of choice for lung cancer - Cisplatin with Taxane

▪️Drug of choice for malignant melanoma - Dacarbazine

▪️Drug of choice for testicular cancer - Bleomycin+ Etoposide + Cisplatin

[thuockedon24h-com]

Thông tin cơ bản về thuốc BDF-FDACell 50 Nhóm thuốc: Thuốc chống ung thư và tác dụng lên hệ thống miễn dịch

Dạng bào chế: Bột pha tiêm

Thành phần:

Fludarabine phosphat 50mg

SDK: VD-23134-15

Nhà sản xuất: Công Ty Cổ Phần Dược Phẩm Vật Tư Y Tế Bình Định – VIỆT NAM

[rnewspost]

Using donor CAR T cells shows promise in treating myeloma patients in phase I trial

CAR T Cell Concentrations Stratified by Response. (a) CAR T cell concentrations among ALLO-715 DL3 patients that received any fludarabine/cyclophosphamide/ALLO-647 (FCA) lymphodepletion are shown in responders and non-responders. Error bars show the interquartile range (IQR) for each data point. (b) CAR T cell concentrations among ALLO-715 DL3 patients that received any FCA lymphodepletion in…

[graymanbriefing]

Supply Chain Brief: Pharmaceuticals BLUF: FDA issues warning on shortages of amoxicillin, more than 40 common drugs and medications at risk due to ingredient disruptions. Supply Chain disruptions linked to India and China have caused a price hike and shortage of active pharmaceutical ingredients in adderall, 32 separate antimicrobial including amoxicillin (antibiotic), IV injections, anesthesia, calcium deficiencies medication, and fludarabine (chemotherapy drug), benzodiazepines, and ADHD. The Food and Drug Administration (FDA) issued an alert la...(CLASSIFIED, our full brief and analysis is available to subscribers at link in bio)

[zany1122]

Fludacel 50mg Injection

Fludacel 50 injection is used in the treatment of B-Cell chronic lymphocytic leukemia (blood cancer). Know about the working, benefits, drug interactions, and safety precautions. Buy fludarabine injection online on GNH India at best PRICE.

READ MORE:https://www.gnhindia.com/products/flu-lifex-50mg-fludarabine-phosphate/

[hkaffilates]

Fludarabine- and low-dose cyclophosphamide-based conditioning regimens provided favorable survival and engraftment for unmanipulated hematopoietic cell transplantation from unrelated donors and matched siblings in patients with Fanconi anemia: results from the CBMTR

Fludarabine- and low-dose cyclophosphamide-based conditioning regimens provided favorable survival and engraftment for unmanipulated hematopoietic cell transplantation from unrelated donors and matched siblings in patients with Fanconi anemia: results from the CBMTR

Dufour C. How I manage patients with Fanconi anaemia. Br J Haematol. 2017;178:32–47. https://doi.org/10.1111/bjh.14615. Article  PubMed  Google Scholar  Locatelli F, Zecca M, Pession A, Morreale G, Longoni D, Di Bartolomeo P, et al. The outcome of children with Fanconi anemia given hematopoietic stem cell transplantation and the influence of fludarabine in the conditioning regimen: a report…

[relationstoday]

Fludarabine- and low-dose cyclophosphamide-based conditioning regimens provided favorable survival and engraftment for unmanipulated hematopoietic cell transplantation from unrelated donors and matched siblings in patients with Fanconi anemia: results from the CBMTR

Fludarabine- and low-dose cyclophosphamide-based conditioning regimens provided favorable survival and engraftment for unmanipulated hematopoietic cell transplantation from unrelated donors and matched siblings in patients with Fanconi anemia: results from the CBMTR

Dufour C. How I manage patients with Fanconi anaemia. Br J Haematol. 2017;178:32–47. https://doi.org/10.1111/bjh.14615. Article  PubMed  Google Scholar  Locatelli F, Zecca M, Pession A, Morreale G, Longoni D, Di Bartolomeo P, et al. The outcome of children with Fanconi anemia given hematopoietic stem cell transplantation and the influence of fludarabine in the conditioning regimen: a report…

[nursingscience]

HEMATOLOGY

▪️Drug of choice for mierocytic anemia - Ferrous Sulfate

▪️Drug of choice for iron deficiency anemia in pregnancy - Ferrous sulphate

▪️Drug of choice for warfarin overdose - Vitamin K

▪️Drug of choice for heparin overdose - Protamine sulphate

▪️Drug of choice for hairy cell leukemia - Cladribine

▪️Drug of choice for chronic lymphocytic leukemia - Fludarabine

▪️Drug of choice for chronic myeloid leukemia (CML) - Imatinib

▪️Drug of choice for chemotherapy-induced anemia - Erythropoietin

▪️Drug of choice for anemia due to chronic kidney disease (CKD) - Erythropoietin

▪️drug of choice for autoimmune hemolytic anemia - Prednisolone

▪️Drug of choice for transient ischemic attack (TIA) - Aspirin

▪️Drug of choice for multiple myeloma - Melphalan

▪️Drug of choice for heparin-induced thrombocytopenia - Argatroban

▪️Drug of choice for chemotherapy-induced leukopenia - Sargramostim

▪️Drug of choice for chemotherapy induced thrombocytopenia - Oprelvekin

▪️First line drugs for multiple myeloma - Prednisolone, Prednisolone, Cyclophosphamide

▪️Drug of choice for heparin-induced thrombocytopenia - Argatroban

▪️Drug of choice for bleeding due to heparin - Hirudin

▪️Drug of choice for warfarin overdose - Vitamin K

▪️Drug of choice for heparin overdose - Protamine

▪️Thrombolytic agent of choice in acute myocardial infarction - Streptokinase

▪️Drug of choice for arterial fibrillation induced clotting - Warfarin

▪️Drug of choice for prevention of stroke - Aspirin

▪️Drug of choice for prevention of deep vein thrombosis - Low molecular weight heparin (LMWH)

▪️Drug of choice for preventing bleeding due to thrombolytic therapy-Epsilion amino capronic acid

▪️Drug of choice for treatment of deep vein thrombosis - Low molecular weight heparin (LMWH)

▪️Drug of choice for pulmonary embolism - Low molecular weight heparin (LMWH)

▪️Drug of choice for anemia in chronic renal failure - Erythropoietin

[ptmasterguide]

Fludarabine

In this article, we will discuss about Fludarabine (Clinical Pharmacology). So, let’s get started. Fludarabine phosphate is rapidly dephosphorylated to 2-fluoro-ara-A and then phosphorylated intracellularly by deoxycytidine kinase to the active triphosphate, 2-fluoro-ara-ATP. This metabolite appears to act by inhibiting DNA polymerase alpha, ribonucleotide reductase and DNA primase, thus…